

# 2-Methylene-19-Nor-1Alpha-Hydroxy-17-Ene-Homopregnacalciferol

### View U.S. Patent No. 7,241,750 in PDF format.

### WARF: P05148US

Inventors: Hector DeLuca, Lori Plum, Bulli Padmaja Tadi, Margaret Clagett-Dame

### The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a new vitamin D analog.

### **Overview**

Vitamin D is a highly potent regulator of calcium homeostasis and plays an established role in cellular differentiation. A recently discovered class of vitamin D analogs, the 19-nor-vitamin D compounds, shows a selective activity profile with high potency in inducing cellular differentiation and very low calcium mobilizing activity. These features make the 19-nor compounds potentially useful as therapeutic agents for a number of disorders.

## The Invention

UW-Madison researchers have developed a new vitamin D analog, 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol. This compound, a 2-methylene-19-nor-17-ene vitamin D analog, is characterized by a hydroxyl group at carbon 1, a methylene substituent at carbon 2, a double bond between carbons 17 and 20 and the elimination of carbons 23,24,25,26 and 27.

Compared to 1a,25-dihydroxyvitamin D<sub>3</sub>, the new analog exhibits relatively high binding to vitamin D receptors, very low intestinal calcium transport activity, and very low ability to mobilize calcium from bone. It also displays relatively high cell differentiation activity, making it potentially useful as an anti-cancer agent or a therapeutic agent for treating skin conditions.

## **Applications**

- · Potential anti-cancer agent, especially against leukemia, and colon, breast and prostate cancers
- · Preventing or treating obesity and reduce body fat
- Treating skin diseases, such as psoriasis, as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion
- · Potential for treating immune disorders in humans, including multiple sclerosis, lupus, diabetes mellitus, host-versus-graft reaction and organ transplant rejection
- · Prospective treatment for inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel diseases
- · Promising treatment for renal osteodystrophy
- Treating other disorders, including acne, alopecia and hypertension

## Additional Information

### For More Information About the Inventors

<u>Margaret Clagett-Dame</u>
We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete
 <u>Tech Fields</u>
 cookies, you agree to the storing of cookies and related technologies on your device. <u>See our privacy policy</u>

Therapeutics & Vaccines : Vitamin D



For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. See our privacy policy

